Évaluation du fer sérique comme facteur prédictif d’une réponse de l’hémoglobine au traitement par fer injectable chez les patients hémodialysés chroniques

IF 0.7 4区 医学 Q4 UROLOGY & NEPHROLOGY Nephrologie & Therapeutique Pub Date : 2022-12-01 DOI:10.1016/j.nephro.2022.03.008
Clarisse Grèze , Cyril Garrouste , Bruno Pereira , Mohammed Hadj-Abdelkader , Anne-Élisabeth Heng , Julien Aniort
{"title":"Évaluation du fer sérique comme facteur prédictif d’une réponse de l’hémoglobine au traitement par fer injectable chez les patients hémodialysés chroniques","authors":"Clarisse Grèze ,&nbsp;Cyril Garrouste ,&nbsp;Bruno Pereira ,&nbsp;Mohammed Hadj-Abdelkader ,&nbsp;Anne-Élisabeth Heng ,&nbsp;Julien Aniort","doi":"10.1016/j.nephro.2022.03.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The detection and correction of iron deficiency are essential for the treatment of anemia in chronic hemodialysis patients. The aim of our study was to assess the ability of serum iron to predict hemoglobin response to intravenous iron supplementation in hemodialysis patients.</p></div><div><h3>Methods</h3><p>It is a retrospective study in 91 hemodialysis patients during 2016 at Clermont-Ferrand University Hospital for whom intravenous iron supplementation had been started. A responder patient was defined as an increase in hemoglobin greater than or equal to 1 g/dL/month and/or a decrease in the dose of erythropoiesis stimulating agent after two months of iron supplementation.</p></div><div><h3>Results</h3><p>In responding patients, serum iron was significantly lower (6.7 ± 2.7 μmol/L) compared to non-responding patients (8.9<!--> <!-->±<!--> <!-->2.9 μmol/L; <em>P</em> <!-->&lt;<!--> <!-->0.001). The positive response to iron supplementation was significantly associated with low serum iron (odds ratio = 0.58 [0.42–0.81]; <em>P</em> <!-->=<!--> <!-->0.002) in a logistic regression model taking into account ferritin, transferrin saturation coefficient, dose variation monthly iron and erythropoiesis stimulating agent and the duration of dialysis. The area under the receiver operating characteristic curve of serum iron, ferritin and transferrin saturation coefficient to predict the response to iron supplementation were 0.72, 0.51 and 0.64, respectively (serum iron versus ferritin [<em>P</em> <!-->=<!--> <!-->0.006] and serum iron versus transferrin saturation coefficient [<em>P</em> <!-->=<!--> <!-->0.04]). The sensitivity for serum iron below 7.5 μmol/L was better than that for ferritin below 86 ng/mL (<em>P</em> <!-->&lt;<!--> <!-->0.001) and the specificity for serum iron below 7.5 μmol/L was better than that for TSC less than 19% (<em>P</em> <!-->=<!--> <!-->0.02).</p></div><div><h3>Conclusion</h3><p>Serum iron below 7.5 μmol/L can predict the success of the response to iron supplementation in chronic hemodialysis patients.</p></div>","PeriodicalId":51140,"journal":{"name":"Nephrologie & Therapeutique","volume":"18 7","pages":"Pages 634-642"},"PeriodicalIF":0.7000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephrologie & Therapeutique","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1769725522001080","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The detection and correction of iron deficiency are essential for the treatment of anemia in chronic hemodialysis patients. The aim of our study was to assess the ability of serum iron to predict hemoglobin response to intravenous iron supplementation in hemodialysis patients.

Methods

It is a retrospective study in 91 hemodialysis patients during 2016 at Clermont-Ferrand University Hospital for whom intravenous iron supplementation had been started. A responder patient was defined as an increase in hemoglobin greater than or equal to 1 g/dL/month and/or a decrease in the dose of erythropoiesis stimulating agent after two months of iron supplementation.

Results

In responding patients, serum iron was significantly lower (6.7 ± 2.7 μmol/L) compared to non-responding patients (8.9 ± 2.9 μmol/L; P < 0.001). The positive response to iron supplementation was significantly associated with low serum iron (odds ratio = 0.58 [0.42–0.81]; P = 0.002) in a logistic regression model taking into account ferritin, transferrin saturation coefficient, dose variation monthly iron and erythropoiesis stimulating agent and the duration of dialysis. The area under the receiver operating characteristic curve of serum iron, ferritin and transferrin saturation coefficient to predict the response to iron supplementation were 0.72, 0.51 and 0.64, respectively (serum iron versus ferritin [P = 0.006] and serum iron versus transferrin saturation coefficient [P = 0.04]). The sensitivity for serum iron below 7.5 μmol/L was better than that for ferritin below 86 ng/mL (P < 0.001) and the specificity for serum iron below 7.5 μmol/L was better than that for TSC less than 19% (P = 0.02).

Conclusion

Serum iron below 7.5 μmol/L can predict the success of the response to iron supplementation in chronic hemodialysis patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
慢性血液透析患者血清铁作为血红蛋白对注射铁治疗反应的预测因子的评价
背景缺铁的检测和纠正对慢性血液透析患者贫血的治疗至关重要。我们研究的目的是评估血清铁预测血液透析患者对静脉补铁的血红蛋白反应的能力。方法对2016年在克莱蒙费朗大学医院开始静脉补铁的91例血液透析患者进行回顾性研究。有反应的患者被定义为在补充铁两个月后血红蛋白增加大于或等于1 g/dL/月和/或促红细胞生成剂剂量减少。结果缓解组血清铁含量(6.7±2.7 μmol/L)明显低于无缓解组(8.9±2.9 μmol/L);P & lt;0.001)。铁补充阳性反应与低血清铁显著相关(优势比= 0.58 [0.42-0.81];P = 0.002)在考虑铁蛋白、转铁蛋白饱和系数、剂量变化、每月铁和促红细胞生成剂以及透析持续时间的logistic回归模型中。血清铁、铁蛋白和转铁蛋白饱和系数预测补铁效果的受试者工作特征曲线下面积分别为0.72、0.51和0.64(血清铁对铁蛋白[P = 0.006]和血清铁对转铁蛋白饱和系数[P = 0.04])。血清铁在7.5 μmol/L以下的敏感性优于铁蛋白在86 ng/mL以下的敏感性(P <血清铁< 7.5 μmol/L特异性优于TSC < 19%特异性(P = 0.02)。结论血清铁低于7.5 μmol/L可预测慢性血液透析患者补铁效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Nephrologie & Therapeutique
Nephrologie & Therapeutique 医学-泌尿学与肾脏学
CiteScore
0.80
自引率
14.30%
发文量
485
审稿时长
11.9 weeks
期刊介绍: Organe d''expression de la Société de Néphrologie, de la Société Francophone de Dialyse et de la Société de Néphrologie Pédiatrique, Néphrologie et Thérapeutique a pour vocation de publier des textes en français dans le domaine de la Néphrologie, qu''il s''agisse d''actualisation des connaissances, de recommandations de bonne pratique clinique, de publications originales, ou d''informations sur la vie des trois sociétés fondatrices. La variété des thèmes abordés reflète la richesse de la Néphrologie, qu''il s''agisse d''aspects fondamentaux issus de la physiologie, de l''immunologie, de l''anatomo-pathologie, ou de la génétique, ou de sujets de néphrologie clinique, notamment ceux en rapport avec les thérapeutiques néphrologiques, transplantation, hémodialyse et dialyse péritonéale.
期刊最新文献
Posters Posters commentés Communications orales [Biological parameters for assessment and monitoring anemia in hemodialysis patients]. [Arguments for the use of cardiac biomarkers in hemodialysis: natriuretic peptides and troponins].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1